Spyre Therapeutics, Inc. (SYRE): Total Assets
$777.78M
As of 2025-12-31
$1.17B
As of 2026-06-30
+121.9%
3-year compound annual growth
+36.9%
5-year compound annual growth
+35.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $777.78M | +27.8% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $608.48M | +78.0% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $341.86M | +380.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $71.14M | -35.3% | 2024-11-18, Balance as of period end |
| 2021-12-31 | $109.93M | -32.0% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $161.62M | +94.3% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $83.18M | +7.0% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $77.74M | +38.6% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $56.08M | -16.4% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $67.06M | +73.5% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $38.65M | n/a | 2017-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $777.78M | +27.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare SYRE, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗